Center-Authored Papers

Filters: Author is Were, Edwin  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E et al..  2012.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.. The New England journal of medicine. 367(5):399-410. Abstract
Viral Load
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract
Valine
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
Vaccine and Infectious Disease Institute
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Vaccine and Infectious Disease Division
Ndase P, Celum C, Campbell J, Bukusi E, Kiarie J, Katabira E, Mugo N, Tumwesigye E, Wangisi J, Were E et al..  2014.  Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result: The Partners PrEP Study Experience.. Journal of acquired immune deficiency syndromes (1999). 66(2):206-12. Abstract
Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, Campbell JD, Wangisi J, Tappero JW, Bukusi E et al..  2011.  Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.. PloS one. 6(10):e25828. Abstract
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract
Heffron R, Donnell D, Kiarie J, Rees H, Ngure K, Mugo N, Were E, Celum C, Baeten JM.  2014.  A Prospective Study of the Effect of Pregnancy on CD4 Counts and Plasma HIV-1 RNA Concentrations of Antiretroviral-Naive HIV-1-Infected Women.. Journal of acquired immune deficiency syndromes (1999). 65(2):231-6. Abstract
Heffron R, Mugo N, Ngure K, Celum C, Donnell D, Were E, Rees H, Kiarie J, Baeten JM.  2013.  Hormonal contraceptive use and risk of HIV-1 disease progression.. AIDS (London, England). 27(2):261-267. Abstract
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E et al..  2012.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.. The New England journal of medicine. 367(5):399-410. Abstract
Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, Were E, Mujugira A, Kiarie J, Celum C et al..  2014.  Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception.. AIDS (London, England). Abstract
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT et al..  2014.  Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention: A Randomized Clinical Trial.. JAMA : the journal of the American Medical Association. 312(4):362-71. Abstract
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract
United States
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
sexually transmitted diseases
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Sexual Partners
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Sexual Behavior
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E et al..  2012.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.. The New England journal of medicine. 367(5):399-410. Abstract
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract
Sequence Analysis, DNA
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
Selection, Genetic
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
RNA, Viral
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E et al..  2012.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.. The New England journal of medicine. 367(5):399-410. Abstract
Risk Factors
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract